



Amendments to the Specification:

Please amend the Abstract as follows:

This invention concerns compounds of formula



[[a]]N-oxides, [[a]]pharmaceutically acceptable addition salts, [[a]]quaternary amines and [[a]]stereochemically isomeric forms thereof, wherein ring A represents phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R^1 represents hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyl; C_{1-6} alkyloxy; C_{1-6} alkyl substituted with formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxy; C_{1-6} alkylcarbonyloxy; or optionally substituted C_{1-6} alkyloxy; C_{1-6} alkylcarbonyl; X_1 represents a direct bond; $(CH_2)_{n3}$ or $(CH_2)_{n4}$; X_{1a} and X_{1b} ; R^2 represents optionally substituted C_{3-7} cycloalkyl; phenyl; a 4, 5, 6 or 7 membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N; benzoxazolyl or a radical of formula



X_2 represents a direct bond; NR^1 ; $NR^1(CH_2)_{n3}$; O ; $O(CH_2)_{n3}$; $C(=O)$; $C(=O)(CH_2)_{n3}$; $C(=O)NR^5$; $C(=O)(CH_2)_{n3}$; $C(=S)$; S ; $S(=O)_{n1}$; $(CH_2)_{n3}$; $(CH_2)_{n4}$; X_{1a} and X_{1b} ; X_{1a} and $X_{1b}(CH_2)_{n4}$; $S(=O)_{n1}$; NR^5 ; $(CH_2)_{n3}$; NR^5 or $S(=O)_{n1}$; NR^5 ; $(CH_2)_{n3}$; R^3 represents an optionally substituted 5 or 6 membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N, or a 9 or 10 membered bicyclic heterocycle containing at least one heteroatom selected from O, S or N; R^4 represents hydrogen; halo; hydroxy; optionally substituted C_{1-4} alkyl; optionally substituted C_{2-4} alkenyl or C_{2-4} alkynyl; polyhalo C_{1-3} alkyl; optionally substituted C_{1-4} alkyloxy; polyhalo C_{1-3} alkyloxy; C_{1-4} alkylthio; polyhalo C_{1-3} alkylthio; C_{1-4} alkyloxy; C_{1-4} alkylcarbonyloxy; C_{1-4} alkylcarbonyl; polyhalo C_{1-4} alkylcarbonyl; nitro; cyano; carboxyl; NR^9R^{10} ; $C(=O)NR^9R^{10}$; NR^5 ; $C(=O)NR^9R^{10}$; NR^5 ; $C(=O)R^5$; $S(=O)_{n1}$; R^{11} ; NR^5 ; $S(=O)_{n1}$; R^{11} ; S ; CN ; NR^5 ; CN ; their use, pharmaceutical compositions comprising them, and processes for their preparation.